Copyright © 2012 Rie Nakamoto-Matsubara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Bronchiolitis obliterans (BO) is one of the serious, noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early diagnosis of BO is usually difficult because patients are often asymptomatic at an initial stage of the disease and pathologic findings are available mostly at the late stages. Therefore, the diagnosis of the disease is based on the pulmonary function test using the National Institute of Health consensus criteria. Here,...
Objective: To describe the clinical characteristics and outcomes of patients diagnosed with oblitera...
llogeneic and autologous haematopoietic stem cell (HSC) transplantation are now both established as ...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Introduction: Bronchiolitis Obliterans (BO) is one of the most important pulmonary complications of ...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
AbstractPulmonary dysfunction is a significant complication following allogeneic hematopoietic stem ...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
High-resolution computed tomography (HRCT) has been described to be useful in assessing bronchioliti...
The diagnosis of the obliterative bronchiolitis syndrome in lung transplantation is presently best e...
Bronchiolitis obliterans (BO) is a rare, chronic form of obstructive lung disease, often initiated w...
SummaryObliterative bronchiolitis (OB) is known to result from many causes, such as post-bone marrow...
Objective: To describe the clinical characteristics and outcomes of patients diagnosed with oblitera...
llogeneic and autologous haematopoietic stem cell (HSC) transplantation are now both established as ...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Introduction: Bronchiolitis Obliterans (BO) is one of the most important pulmonary complications of ...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
AbstractPulmonary dysfunction is a significant complication following allogeneic hematopoietic stem ...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
High-resolution computed tomography (HRCT) has been described to be useful in assessing bronchioliti...
The diagnosis of the obliterative bronchiolitis syndrome in lung transplantation is presently best e...
Bronchiolitis obliterans (BO) is a rare, chronic form of obstructive lung disease, often initiated w...
SummaryObliterative bronchiolitis (OB) is known to result from many causes, such as post-bone marrow...
Objective: To describe the clinical characteristics and outcomes of patients diagnosed with oblitera...
llogeneic and autologous haematopoietic stem cell (HSC) transplantation are now both established as ...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...